“The positive results across all three Phase 3 TEMPO trials underscore the potential of tavapadon as a first-in-class D1/D5 ...
Including the acquisition and expansion of the manufacturing facility, Eli Lilly will be investing $4bn in the site. After ...
As part of the deal, Dewpoint can expect an undisclosed upfront payment from Mitsubishi Tanabe Pharma Corporation (MTPC) in ...
Radiopharmaceuticals have also been the target of large partnership deals, including a recent $140 million partnership ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback